• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Minerva Surgical Inc. filed SEC Form 8-K: Leadership Update

    10/13/23 4:22:26 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology
    Get the next $UTRS alert in real time by email
    8-K
    0001452965false00014529652023-10-132023-10-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): October 13, 2023

    Minerva Surgical, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

     

     

    Delaware

     

    001-40919

     

    26-3422906

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    4255 Burton Dr., Santa Clara, CA 95054

    (Address of Principal Executive Offices) (Zip Code)

     

    (855) 646-7874

    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

     

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 par value per share

     

    UTRS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

     

    Item 5.02

    Departure Of Directors or Certain Officers; Election Of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On October 13, 2023, Jill D. Anderson resigned from the Board of Directors of Minerva Surgical, Inc. (the “Company”). Ms. Anderson’s decision to resign was not the result of any disagreement with the policies, procedures or practices of the Company.

     

     

     


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    MINERVA SURGICAL, INC.

     

     

    By:

     

    /s/ Todd Usen

    Name:

     

    Todd Usen

    Title:

     

    Chief Executive Officer

    Date: October 13, 2023.

     


    Get the next $UTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UTRS

    DatePrice TargetRatingAnalyst
    3/9/2022$17.00 → $12.00Overweight
    Piper Sandler
    12/3/2021$17.00 → $12.00Outperform
    SVB Leerink
    11/16/2021$17.00Outperform
    SVB Leerink
    11/16/2021$15.00Buy
    UBS
    11/16/2021$14.00Overweight
    JP Morgan
    11/16/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $UTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Cohen Daniel claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      3/14/23 5:37:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4: New Enterprise Associates 13 Lp bought $5,000,000 worth of shares (24,437,927 units at $0.20)

      4 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/10/23 9:25:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 3: New insider Accelmed Partners Ii L.P. claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/9/23 4:28:55 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      9/28/23 4:43:42 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 8:21:56 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 5:19:24 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Financials

    Live finance-specific insights

    See more

    $UTRS
    Leadership Updates

    Live Leadership Updates

    See more

    $UTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $UTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $UTRS
    SEC Filings

    See more
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical to Announce First Quarter 2023 Financial Results

      SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe

      4/18/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

      SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro

      3/21/23 4:05:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

      SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an

      12/28/22 6:00:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

      SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo

      7/21/22 8:00:00 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Third Quarter 2023 Financial Results

      SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym

      11/13/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Piper Sandler reiterated coverage on Minerva Surgical with a new price target

      Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      3/9/22 6:38:44 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink reiterated coverage on Minerva Surgical with a new price target

      SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously

      12/3/21 9:34:35 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink initiated coverage on Minerva Surgical with a new price target

      SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00

      11/16/21 7:59:25 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 15-12G filed by Minerva Surgical Inc.

      15-12G - MINERVA SURGICAL INC (0001452965) (Filer)

      1/4/24 4:32:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 25 filed by Minerva Surgical Inc.

      25 - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 4:30:25 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form S-8 POS filed by Minerva Surgical Inc.

      S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 12:05:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology